Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs

Future Medicinal Chemistry

Volumn 4, Issue 9, 2012, Pages 1113-1151

  Wang, Jingxin ^a   Hudson, Ryan ^b   Sintim, Herman O ^a  

^a Bldg 142   (United States)

^b THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; ACARBOSE; ACETYL COENZYME A CARBOXYLASE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIOBESITY AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; CISPLATIN; DOXORUBICIN; ERYTHROMYCIN; GLIBENCLAMIDE; LINAGLIPTIN; LINEZOLID; METFORMIN; METHOTREXATE; PACLITAXEL; PHENTERMINE; PIOGLITAZONE; RIMONABANT; SIBUTRAMINE; SORAFENIB; STREPTOMYCIN; SULFAMIDOCHRYSOIDINE; TAMOXIFEN; TETRACYCLINE; TETRAHYDROLIPSTATIN; TIOGUANINE; UNINDEXED DRUG; ZONISAMIDE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL GROWTH; BACTERIAL MEMBRANE; CANCER RESISTANCE; CARDIOTOXICITY; CATALYSIS; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CELL WALL; CHEMICAL STRUCTURE; COMPUTER MODEL; DEPRESSION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MODIFICATION; ESCHERICHIA COLI; EUKARYOTE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HUNGER; HYPOTHALAMUS; IC 50; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MITOCHONDRION; MYCOBACTERIUM TUBERCULOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET ALPHA CELL; PRIORITY JOURNAL; PROKARYOTE; PSEUDOMONAS AERUGINOSA; REVIEW; SATIETY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UPREGULATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; WEIGHT REDUCTION;

ANTI-INFECTIVE AGENTS; ANTI-OBESITY AGENTS; ANTINEOPLASTIC AGENTS; EUKARYOTIC CELLS; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; HUMANS; PROKARYOTIC CELLS; SIGNAL TRANSDUCTION;

EID: 84862533423     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.62     Document Type: Review

References (273)

1. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7(10), 763-777 (2007). (Pubitemid 47469806)
2. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66(12), 5977-5980 (2006).
3. Zhang YM, White SW, Rock CO. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem. 281(26), 17541-17544 (2006). (Pubitemid 44035552)
4. Smith S, Tsai SC. The type I fatty acid and polyketide synthases: a tale of two megasynthases. Nat. Prod. Rep. 24(5), 1041-1072 (2007). (Pubitemid 47493392)
5. Wright HT, Reynolds KA. Antibacterial targets in fatty acid biosynthesis. Curr. Opin. Microbiol. 10(5), 447-453 (2007). (Pubitemid 350052682)
6. Campbell JW, Cronan JE. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 55, 305-332 (2001). (Pubitemid 32978108)
7. Rada PV, Hoebel BG. Supraadditive effect of d-fenfluramine plus phentermine on extracellular acetylcholine in the nucleus accumbens: possible mechanism for inhibition of excessive feeding and drug abuse. Pharmacol. Biochem. Behav. 65(3), 369-373 (2000). (Pubitemid 30100666)
8. Hainer V, Kabrnova K, Aldhoon B, Kunesova M, Wagenknecht M. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann. NY Acad. Sci. 1083, 252-269 (2006). (Pubitemid 44955477)
9. Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab. J. 36(1), 13-25 (2012).
10. Finer N. Sibutramine: its mode of action and efficacy. Int. J. Obes. Relat. Metab. Disord. 26(SUPPL. 4), S29-S33 (2002). (Pubitemid 36071969)
11. Fong TM, Heymsfield SB. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int. J. Obes., 33(9), 947-955 (2009).
12. Hochuli E, Kupfer E, Maurer R, Meister W, Mercadal Y, Schmidt K. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation. J. Antibiot. 40(8), 1086-1091 (1987). (Pubitemid 17141407)
13. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J. Clin. Pharmacol. 35(11), 1103-1108 (1995).
14. Harrison-Woolrych M, Ashton J, Herbison P. Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study. Drug Saf. 33(7), 605-613 (2010).
15. Mitchell PB, Morris MJ. Depression and anxiety with rimonabant. Lancet 370(9600), 1671-1672 (2007). (Pubitemid 350100780)
16. Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central regulation of feeding. Nature 409(6817), 194-198 (2001). (Pubitemid 32144284)
17. Lage R, Vazquez MJ, Varela L et al. Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J. 24(8), 2670-2679 (2010).
18. Barnett BP, Hwang Y, Taylor MS et al. Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science 330(6011), 1689-1692 (2010).
19. Mera P, Bentebibel A, Lopez-Vinas E et al. C75 is converted to C75-CoA in the hypothalamus, where it inhibits carnitine palmitoyltransferase 1 and decreases food intake and body weight. Biochem. Pharmacol. 77(6), 1084-1095 (2009).
20. Petersen KF, Oral EA, Dufour S et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109(10), 1345-1350 (2002). (Pubitemid 34546899)
21. Kim YD, Park KG, Lee YS et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57(2), 306-314 (2008).
22. Donath MY, Ehses JA, Maedler K et al. Mechanisms of beta-cell death in Type 2 diabetes. Diabetes 54(SUPPL. 2), S108-S113 (2005). (Pubitemid 43343338)
23. Luzi L, Pozza G. Glibenclamide: an old drug with a novel mechanism of action? Acta Diabetol. 34(4), 239-244 (1997). (Pubitemid 28010552)
24. Samulitis BK, Goda T, Lee SM, Koldovsky O. Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp. Clin. Res., 13(8), 517-524 (1987). (Pubitemid 17146556)
25. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for Type 2 diabetes mellitus. Ann. Intern. Med. 147(6), 386-399 (2007). (Pubitemid 351664540)
26. Nomura S, Sakamaki S, Hongu M et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of Type 2 diabetes mellitus. J. Med. Chem. 53(17), 6355-6360 (2010).
27. Zhang L, Keung W, Samokhvalov V, Wang W, Lopaschuk GD. Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochim. Biophys. Acta 1801(1), 1-22 (2010).
28. Espinosa E, Zamora P, Feliu J, Gonzalez Baron M. Classification of anticancer drugs-a new system based on therapeutic targets. Cancer Treat. Rev. 29(6), 515-523 (2003). (Pubitemid 37428323)
29. Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc. Natl Acad. Sci. USA 99(21), 13481-13486 (2002). (Pubitemid 35215407)
30. Waters TR, Swann PF. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 36(9), 2501-2506 (1997). (Pubitemid 27106642)
31. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99(9), 2467-2498 (1999).
32. Fuertes MA, Castilla J, Alonso C, Perez JM. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem. 10(3), 257-266 (2003). (Pubitemid 36131658)
33. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta 1400(1-3), 139-154 (1998). (Pubitemid 28475100)
34. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310(3), 1062-1075 (2004). (Pubitemid 39108928)
35. Iorns E, Lord CJ, Ashworth A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem. J. 417(1), 361-370 (2009).
36. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann. Oncol. 5(SUPPL. 6), S3-S6 (1994).
37. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658), 404-407 (1997). (Pubitemid 28027321)
38. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7(10), 3129-3140 (2008).
39. Chen KF, Chen HL, Tai WT et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 337(1), 155-161 (2011).
40. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21(17), 3194-3200 (2003). (Pubitemid 46606249)
41. Gottesman MM. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627 (2002). (Pubitemid 34177898)
42. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004). (Pubitemid 40051905)
43. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4(12), 988-1004 (2005).
44. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11(5), 325-337 (2011).
45. Menendez JA, Vellon L, Mehmi I et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl Acad. Sci. USA 101(29), 10715-10720 (2004). (Pubitemid 38955808)
46. Liu H, Liu JY, Wu X, Zhang JT. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int. J. Biochem. Mol. Biol. 1(1), 69-89 (2010).
47. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38(4), 521-528 (2004). (Pubitemid 38250962)
48. McDermott PF, Zhao S, Wagner DD, Simjee S, Walker RD, White DG. The food safety perspective of antibiotic resistance. Anim. Biotechnol. 13(1), 71-84 (2002).
49. White DG, Zhao S, Sudler R et al. The isolation of antibiotic-resistant salmonella from retail ground meats. N. Engl. J. Med. 345(16), 1147-1154 (2001).
50. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N. Engl. J. Med. 356(7), 656-659 (2007).
51. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368(9538), 874-885 (2006). (Pubitemid 44308640)
52. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046-5054 (2009).
53. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of metallo-beta-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob. Agents Chemother. 54(11), 4914-4916 (2010).
54. Mochon AB, Garner OB, Hindler JA et al. New Delhi metallo-beta-lactamase (NDM-1)-producing Klebsiella pneumoniae: case report and laboratory detection strategies. J. Clin. Microbiol. 49(4), 1667-1670 (2011).
55. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295(5562), 2042-2046 (2002). (Pubitemid 34229458)
56. Shah NS, Wright A, Bai GH et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13(3), 380-387 (2007). (Pubitemid 46348124)
57. Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg. Infect. Dis. 4(2), 239-249 (1998). (Pubitemid 28311210)
58. Kollef MH. Gram-negative bacterial resistance: evolving patterns and treatment paradigms. Clin. Infect. Dis. 40 (S2), S85-S88 (2005). (Pubitemid 40270205)
59. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34(5), 634-640 (2002). (Pubitemid 34165326)
60. Li XZ, Ma D, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrob. Agents Chemother. 38(8), 1742-1752 (1994). (Pubitemid 24250719)
61. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44(9), 2242-2246 (2000). (Pubitemid 30650862)
62. Li XZ, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob. Agents Chemother. 38(8), 1732-1741 (1994). (Pubitemid 24250718)
63. Schweizer HP. Intrinsic resistance to inhibitors of fatty acid biosynthesis in Pseudomonas aeruginosa is due to efflux: application of a novel technique for generation of unmarked chromosomal mutations for the study of efflux systems. Antimicrob. Agents Chemother. 42(2), 394-398 (1998). (Pubitemid 28114451)
64. D'Costa VM, King CE, Kalan L et al. Antibiotic resistance is ancient. Nature 477(7365), 457-461 (2011).
65. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10(9), 597-602 (2010).
66. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of metallo-beta-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob. Agents Chemother. 54(11), 4914-4916 (2010).
67. Poirel L, Revathi G, Bernabeu S, Nordmann P. Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. Antimicrob. Agents Chemother. 55(2), 934-936 (2011).
68. Mulvey MR, Grant JM, Plewes K, Roscoe D, Boyd DA. New Delhi metallo-beta-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada. Emerg. Infect. Dis. 17(1), 103-106 (2011).
69. WHO. The Global Plan to Stop TB, 2011-2015. WHO, Geneva, Switzerland (2010)
70. Mediterranean E. The Global Tuberculosis Epidemic; Nov. 2010-Fact Sheet; No. 7883-7802. Kaiser Family Foundation, Menlo Park, CA, USA (2010).
71. Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 399(6736), 590-593 (1999).
72. Chiosis G, Boneca IG. Selective cleavage of d-Ala-d-Lac by small molecules: re-sensitizing resistant bacteria to vancomycin. Science 293(5534), 1484-1487 (2001). (Pubitemid 32801550)
73. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1(8575-8576), 57-58 (1988). (Pubitemid 18017235)
74. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J. Antimicrob. Chemother. 44(2), 251-261 (1999). (Pubitemid 29389289)
75. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34(11), 1481-1490 (2002). (Pubitemid 34553708)
76. Tally FP, Zeckel M, Wasilewski MM et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin. Investig. Drugs 8(8), 1223-1238 (1999). (Pubitemid 29410579)
77. Schmitz FJ, Sadurski R, Stattfeld A, Kray A, Verhoef J, Fluit AC. Cross-resistance analyses and molecular typing of Staphylococcus aureus and Streptococcus spp. isolates resistant to quinupristin/dalfopristin. J. Antimicrob. Chemother. 44(6), 847-849 (1999).
78. Lewis JS 2nd, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 49(4), 1664-1665 (2005). (Pubitemid 40463418)
79. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358(9277), 207-208 (2001). (Pubitemid 32718546)
80. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 175(23), 720-731 (1972).
81. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71, 635-700 (2002). (Pubitemid 34800232)
82. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu. Rev. Biochem. 64, 29-63 (1995).
83. Minnikin DE, Kremer L, Dover LG, Besra GS. The methyl-branched fortifications of Mycobacterium tuberculosis. Chem. Biol. 9, 545-553 (2002). (Pubitemid 34593035)
84. Witkowski A, Ghosal A, Joshi AK, Witkowska HE, Asturias FJ, Smith S. Head-to-head coiled arrangement of the subunits of the animal fatty acid synthase. Chem. Biol. 11(12), 1667-1676 (2004). (Pubitemid 39651301)
85. Asturias FJ, Chadick JZ, Cheung IK et al. Structure and molecular organization of mammalian fatty acid synthase. Nat. Struct. Mol. Biol. 12(3), 225-232 (2005). (Pubitemid 43079363)
86. Wakil SJ, Porter JW, Gibson DM. Studies on the mechanism of fatty acid synthesis. 1. Preparation and purification of an enzyme system for reconstruction of fatty acid synthesis. J. Biochim. Biophys. Acta 24(3), 453-461 (1957).
87. Hiltunen JK, Schonauer MS, Autio KJ, Mittelmeier TM, Kastaniotis AJ, Dieckmann CL. Mitochondrial fatty acid synthesis type II: more than just fatty acids. J. Biol. Chem. 284(14), 9011-9015 (2009).
88. Kridel SJ, Lowther WT, Pemble CW. Fatty acid synthase inhibitors: new directions for oncology. Expert Opin. Inv. Drug. 16(11), 1817-1829 (2007). (Pubitemid 350187394)
89. Lomakin IB, Xiong Y, Steitz TA. The crystal structure of yeast fatty acid synthase, a cellular machine with eight active sites working together. Cell 129(2), 319-332 (2007). (Pubitemid 46574968)
90. Maier T, Jenni S, Ban N. Architecture of mammalian fatty acid synthase at 4.5 Å resolution. Science 311(5765), 1258-1262 (2006). (Pubitemid 43334709)
91. Maier T, Leibundgut M, Boehringer D, Ban N. Structure and function of eukaryotic fatty acid synthases. Q. Rev. Biophys. 43(3), 373-422 (2010).
92. Smith S, Witkowski A, Joshi AK. Structural and functional organization of the animal fatty acid synthase. Prog. Lipid Res. 42(4), 289-317 (2003). (Pubitemid 36411688)
93. Abu-Elheiga L, Brinkley WR, Zhong L, Chirala SS, Woldegiorgis G, Wakil SJ. The subcellular localization of acetyl-CoA carboxylase 2. Proc. Natl Acad. Sci. USA 97(4), 1444-1449 (2000). (Pubitemid 30118460)
94. Yu LP, Kim YS, Tong L. Mechanism for the inhibition of the carboxyltransferase domain of acetyl-coenzyme A carboxylase by pinoxaden. Proc. Natl Acad. Sci. USA 107(51), 22072-22077 (2010).
95. Lee CK, Cheong HK, Ryu KS et al. Biotinoyl domain of human acetyl-CoA carboxylase: structural insights into the carboxyl transfer mechanism. Proteins Struct. Funct. Bioinf. 72(2), 613-624 (2008).
96. Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28(11), 4523-4530 (1989). (Pubitemid 19151020)
97. Wakil SJ, Stoops JK, Joshi VC. Fatty acid synthesis and its regulation. Annu. Rev. Biochem. 52, 537-579 (1983). (Pubitemid 13030689)
98. Chen Z, Leskinen H, Liimatta E et al. Myocardial overexpression of Mecr, a gene of mitochondrial FAS II leads to cardiac dysfunction in mouse. PLoS ONE 4(5), e5589 (2009).
99. Schneider R, Massow M, Lisowsky T, Weiss H. Different respiratory-defective phenotypes of Neurospora crassa and Saccharomyces cerevisiae after inactivation of the gene encoding the mitochondrial acyl carrier protein. Curr. Genet. 29(1), 10-17 (1995). (Pubitemid 26013570)
100. Witkowski A, Joshi AK, Smith S. Coupling of the de novo fatty acid biosynthesis and lipoylation pathways in mammalian mitochondria. J. Biol. Chem. 282(19), 14178-14185 (2007). (Pubitemid 47100454)
101. Guler JL, Kriegova E, Smith TK, Lukes J, Englund PT. Mitochondrial fatty acid synthesis is required for normal mitochondrial morphology and function in Trypanosoma brucei. Mol. Microbiol. 67(5), 1125-1142 (2008). (Pubitemid 351207338)
102. Morita YS, Paul KS, Englund PT. Specialized fatty acid synthesis in African trypanosomes: myristate for GPI anchors. Science 288(5463), 140-143 (2000). (Pubitemid 30203047)
103. Yi X, Maeda N. Endogenous production of lipoic acid is essential for mouse development. Mol. Cell. Biol. 25(18), 8387-8392 (2005). (Pubitemid 41263026)
104. Parsons JB, Rock CO. Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr. Opin. Microbiol. 14(5), 544-549 (2011).
105. Lu YJ, Zhang YM, Grimes KD, Qi J, Lee RE, Rock CO. Acyl-phosphates initiate membrane phospholipid synthesis in Gram-positive pathogens. Mol. Cell 23(5), 765-772 (2006). (Pubitemid 44292558)
106. Smith S, Witkowski A, Joshi AK. Structural and functional organization of the animal fatty acid synthase. Prog. Lipid Res. 42(4), 289-317 (2003). (Pubitemid 36411688)
107. Lu YJ, Zhang YM, Rock CO. Product diversity and regulation of type II fatty acid synthases. Biochem. Cell Biol. 82(1), 145-155 (2004). (Pubitemid 38580880)
108. Kaneda T. Fatty acids of the genus Bacillus: an example of branched-chain preference. Bacteriol. Rev. 41(2), 391-418 (1977). (Pubitemid 8146393)
109. Cronan JE, Waldrop GL. Multi-subunit acetyl-CoA carboxylases. Prog. Lipid Res. 41, 407 (2002).
110. Lambalot RH, Walsh CT. Cloning, overproduction, and characterization of the Escherichia coli holo-acyl carrier protein synthase. J. Biol. Chem. 270(42), 24658 (1995).
111. Kuhajda FP, Jenner K, Wood FD et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl Acad. Sci. USA 91(14), 6379-6383 (1994). (Pubitemid 24200664)
112. White SW, Zheng J, Zhang YM, Rock CO. The structural biology of type II fatty acid biosynthesis. Annu. Rev. Biochem. 74, 791-831 (2005). (Pubitemid 40995524)
113. Qiu X, Janson CA, Konstantinidis AK et al. Crystal structure of beta-ketoacyl-acyl carrier protein synthase III. A key condensing enzyme in bacterial fatty acid biosynthesis. J. Biol. Chem. 274(51), 36465-36471 (1999).
114. Haapalainen AM, Merilainen G, Wierenga RK. The thiolase superfamily: condensing enzymes with diverse reaction specificities. Trends Biochem. Sci. 31(1), 64-71 (2006). (Pubitemid 43117544)
115. Schaefer AL, Val DL, Hanzelka BL, John E, Cronan JE Jr, Greenberg EP. Generation of cell-to-cell signals in quorum sensing: acyl homoserine lactone synthase activity of a purified Vibrio fischeri LuxI protein. Proc. Natl Acad. Sci. USA 93, 9505 (1996).
116. Raetz CRH, Garrett TA, Reynolds CM et al. Kdo2-lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J. Lipid Res. 47, 1097 (2006).
117. Harwood HJ Jr. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin. Ther. Targets 9(2), 267-281 (2005). (Pubitemid 40613868)
118. Zhang H, Tweel B, Li J, Tong L. Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with CP-640186. Structure 12(9), 1683-1691 (2004). (Pubitemid 39200520)
119. Corbett JW, Freeman-Cook KD, Elliott R et al. Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2. Bioorg. Med. Chem. Lett. 20(7), 2383-2388 (2010).
120. Harwood HJ Jr, Petras SF, Shelly LD et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J. Biol. Chem. 278(39), 37099-37111 (2003). (Pubitemid 37175224)
121. Schupp T, Toupet C, Cluzel B et al. A Sorangium cellulosum (myxobacterium) gene cluster for the biosynthesis of the macrolide antibiotic soraphen A: cloning, characterization, and homology to polyketide synthase genes from actinomycetes. J. Bacteriol. 177(13), 3673-3679 (1995).
122. Vahlensieck HF, Pridzun L, Reichenbach H, Hinnen A. Identification of the yeast ACC1 gene product (acetyl-CoA carboxylase) as the target of the polyketide fungicide soraphen A. Curr. Genet. 25(2), 95-100 (1994). (Pubitemid 24025638)
123. Beckers A, Organe S, Timmermans L et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 67(17), 8180-8187 (2007). (Pubitemid 47395154)
124. Fredenhagen A, Tamura SY, Kenny PTM, Komura H, Naya Y, Nakanishi K. Andrimid, a new peptide antibiotic produced by an intracellular bacterial symbiont isolated from a brown planthopper. J. Am. Chem. Soc. 109(14), 4409 (1987).
125. Davies SG, Dixon DJ. Asymmetric syntheses of moiramide B and andrimid. J. Chem. Soc. Perkin Trans. 1, 2635-2644 (1998).
126. Freiberg C, Brunner NA, Schiffer G et al. Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J. Biol. Chem. 279(25), 26066 (2004).
127. Lin T-W, Melgar MM, Kurth D et al. Structure-based inhibitor design of AccD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 3072-3077 (2006). (Pubitemid 43346426)
128. Lin T-W, Nguyen T, Kurth D et al. Structure-based inhibitor design of AccD5/AccD6, essential carboxyltransferases of Mycobacterium tuberculosis. FASEB J. 33, 839-834 (2008).
129. Kurth DG, Gago GM, Iglesia Adl et al. Accase 6 is the essential acetyl-CoA carboxylase involved in fatty acid and mycolic acid biosynthesis in mycobacteria. Microbiology 155, 2664 (2009).
130. Levert KL, Waldrop GL, Stephens JM. A biotin analog inhibits acetyl-CoA carboxylase activity and adipogenesis. J. Biol. Chem. 277(19), 16347-16350 (2002). (Pubitemid 34967642)
131. Levert KL, Waldrop GL. A bisubstrate analog inhibitor of the carboxyltransferase component of acetyl-CoA carboxylase. Biochem. Biophys. Res. Commun. 291(5), 1213-1217 (2002). (Pubitemid 34694319)
132. Chu M, Mierzwa R, Xu L et al. Structure elucidation of Sch 538415, a novel acyl carrier protein synthase inhibitor from a microorganism. Bioorg. Med. Chem. Lett. 13, 3827 (2003).
133. Gilbert AM, Kirisits M, Toy P et al. Anthranilate 4H-oxazol-5-ones: novel small molecule antibacterial acyl carrier protein synthase (AcpS) inhibitors. Bioorg. Med. Chem. Lett. 14, 37-41 (2004). (Pubitemid 38010190)
134. Joseph-McCarthy D, Parris K, Huang A et al. Use of structure-based drug design approaches to obtain novel anthranilic acid acyl carrier protein synthase inhibitors. J. Med. Chem. 48, 7960-7069 (2005).
135. Liu W, Han C, Hua L, Chen K, Shen X, Jiang H. Characterization and inhibitor discovery of one novel malonyl-CoA: acyl carrier protein transacylase (MCAT) from Helicobacter pylori. FEBS Lett. 580(2), 697-702 (2006). (Pubitemid 43089708)
136. Price AC, Rock CO, White SW. The 1.3-angstrom-resolution crystal structure of beta-ketoacyl-acyl carrier protein synthase II from Streptococcus pneumoniae. J. Bacteriol. 185(14), 4136-4143 (2003). (Pubitemid 36835253)
137. Oishi H, Noto T, Sasaki H et al. Thiolactomycin, a new antibiotic. I. Taxonomy of the producing organism, fermentation and biological properties. J. Antibiot. (Tokyo) 35, 391-395 (1982). (Pubitemid 12046392)
138. Campbell JW, Cronan JE. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 55, 305-332 (2001). (Pubitemid 32978108)
139. Machutta CA, Bommineni GR, Luckner SR et al. Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin. J. Biol. Chem. 285(9), 6161-6169 (2009).
140. Matsumae A, Nomura S, Hata T. Studies on cerulenin. IV. Biological characteristics of cerulenin. J. Antibiot. (Tokyo) 17, 1 (1964).
141. Li XC, Joshi AS, ElSohly HN et al. Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies. J. Nat. Prod. 65(12), 1909-1914 (2002). (Pubitemid 36055446)
142. Price AC, Choi K-H, Heath RJ, Li Z, White SW, Rock CO. Inhibition of b-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. J. Biol. Chem. 276(9), 6551-6555 (2001).
143. Moche M, Schneider G, Edwards P, Dehesh K, Lindqvist Y. Structure of the complex between the antibiotic cerulenin and its target, b-ketoacyl-acyl carrier protein synthase. J. Biol. Chem. 274(10), 6031-6034 (1999). (Pubitemid 29111003)
144. Morisaki N, Funabashi H, Shimazawa R et al. Effect of side-chain structure on inhibition of yeast fatty-acid synthase by cerulenin analogues. Eur. J. Biochem. 211, 111-115 (1993). (Pubitemid 23039503)
145. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl Acad. Sci. USA 97(7), 3450-3454 (2000). (Pubitemid 30183323)
146. Thupari JN, Kim EK, Moran TH, Ronnett GV, Kuhajda FP. Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass. Am. J. Physiol. Endocrinol. Metab. 287(1), E97-E104 (2004). (Pubitemid 38856288)
147. Wang X, Lin J, Chen Y et al. Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies. Bioorg. Med. Chem. 17(5), 1898-1904 (2009).
148. Wang X, Zhao G, Chen Y et al. 1-oxo-3-substitute-isothiochroman-4- carboxylic acid compounds: synthesis and biological activities of FAS inhibition. Bioorg. Med. Chem. Lett. 19(3), 770-772 (2009).
149. Liu X, Shi Y, Giranda VL, Luo Y. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol. Cancer Ther. 5(3), 494-501 (2006).
150. Cha SH, Hu Z, Chohnan S, Lane MD. Inhibition of hypothalamic fatty acid synthase triggers rapid activation of fatty acid oxidation in skeletal muscle. Proc. Natl Acad. Sci. USA 102(41), 14557-14562 (2005). (Pubitemid 41457096)
151. Tu Y, Thupari JN, Kim EK et al. C75 alters central and peripheral gene expression to reduce food intake and increase energy expenditure. Endocrinology 146(1), 486-493 (2005). (Pubitemid 40051775)
152. Zhang YM, Hurlbert J, White SW, Rock CO. Roles of the active site water, histidine 303, and phenylalanine 396 in the catalytic mechanism of the elongation condensing enzyme of Streptococcus pneumoniae. J. Biol. Chem. 281(25), 17390-17399 (2006).
153. Miyakawa S, Suzuki K, Noto T, Harada Y, Okazaki H. Thiolactomycin, a new antibitoic. IV. Biological properties and chemotherapeutic activity in mice. J. Antibiot. (Tokyo) 35, 411-419 (1982). (Pubitemid 12046395)
154. Omura S, Iwai Y, Nakagawa A et al. Thiotetromycin, a new antibiotic. Taxonomy, production, isolation, and physicochemical and biological properties. J. Antibiot. (Tokyo) 36, 109-114 (1983). (Pubitemid 13148116)
155. McFadden JM, Medghalchi SM, Thupari JN et al. Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. J. Med. Chem. 48(4), 946-961 (2005). (Pubitemid 40270441)
156. Rivkin A, Kim YR, Goulet MT et al. 3-aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors. Bioorg. Med. Chem. Lett. 16(17), 4620-4623 (2006). (Pubitemid 44094061)
157. Zeng XF, Li WW, Fan HJ et al. Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain. Bioorg. Med. Chem. Lett. 21(16), 4742-4744 (2011).
158. Kodali S, Galgoci A, Young K et al. Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J. Biol. Chem. 280, 1669-1669 (2005).
159. Young K, Jayasuriya H, Ondeyka JG et al. Discovery of FabH/FabF inhibitors from natural products. Antimicrob. Agents Chemother. 50(2), 519 (2006).
160. Wang J, Soisson SM, Young K et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441(7091), 358-361 (2006). (Pubitemid 44050201)
161. Wang J, Kodali S, Lee SH et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl Acad. Sci. USA 104(18), 7612-7616 (2007). (Pubitemid 47185954)
162. Wang J, Lee V, Sintim HO. Efforts towards the identification of simpler platensimycin analogues-the total synthesis of oxazinidinyl platensimycin. Chem. Eur. J. 15, 2747 (2009).
163. Shen HC, Ding FX, Singh SB et al. Synthesis and biological evaluation of platensimycin analogs. Bioorg. Med. Chem. Lett. 19(6), 1623-1627 (2009).
164. Nicolaou KC, Stepan AF, Lister T et al. Design, synthesis, and biological evaluation of platensimycin analogues with varying degrees of molecular complexity. J. Am. Chem. Soc. 130(39), 13110-13119 (2008).
165. Walsh CT, Haynes SW, Ames BD. Aminobenzoates as building blocks for natural product assembly lines. Nat. Prod. Rep. 29, 37-59 (2012).
166. Wu M, Singh SB, Wang J et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc. Natl Acad. Sci. USA 108(13), 5378-5383 (2011).
167. Burcelin R, Serino M, Chabo C, Blasco-Baque V, Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol. 48(4), 257-273 (2011).
168. He X, Reynolds KA. Purification, characterization, and identification of novel inhibitors of the b-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus. Antimicrob. Agents Chemother. 46(5), 1310 (2002).
169. Nie Z, Perretta C, Lu J et al. Structure-based design, synthesis, and study of potent inhibitors of b-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. J. Med. Chem. 48, 1596-1609 (2005). (Pubitemid 40364566)
170. Lee JY, Jeong KW, Lee JU, Kang DI, Kim Y. Novel E. coli beta-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics. Bioorg. Med. Chem. 17(4), 1506-1513 (2009).
171. Lee JY, Jeong KW, Shin S, Lee JU, Kim Y. Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors. Bioorg. Med. Chem. 17(15), 5408-5413 (2009).
172. Patel MP, Liu WS, West J, Tew D, Meek TD, Thrall SH. Kinetic and chemical mechanisms of the fabG-encoded Streptococcus pneumoniae beta-ketoacyl-ACP reductase. Biochemistry 44(50), 16753-16765 (2005). (Pubitemid 41832056)
173. Price AC, Zhang YM, Rock CO, White SW. Cofactor-induced conformational rearrangements establish a catalytically competent active site and a proton relay conduit in FabG. Structure 12(3), 417-428 (2004). (Pubitemid 38353063)
174. Silva RG, de Carvalho LP, Blanchard JS, Santos DS, Basso LA. Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein (ACP) reductase: kinetic and chemical mechanisms. Biochemistry 45(43), 13064-13073 (2006). (Pubitemid 44763429)
175. Wang X, Tian WX. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem. Biophys. Res. Commun. 288(5), 1200-1206 (2001). (Pubitemid 33131728)
176. Wang X, Song KS, Guo QX, Tian WX. The galloyl moiety of green tea catechins is the critical structural feature to inhibit fatty-acid synthase. Biochem. Pharmacol. 66(10), 2039-2047 (2003). (Pubitemid 37352867)
177. Zhang Y-M, Rock CO. Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase. J. Biol. Chem. 279(30), 30994-31001 (2004). (Pubitemid 39037758)
178. Yang L, Liu Y, Sternberg C, Molin S. Evaluation of enoyl-acyl carrier protein reductase inhibitors as pseudomonas aeruginosa quorum-quenching reagents. Molecules 15(2), 780-792 (2010).
179. Kumar G, Parasuraman P, Sharma SK et al. Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. J. Med. Chem. 50(11), 2665-2675 (2007). (Pubitemid 46896074)
180. Wang H, Cronan JE. Functional replacement of the FabA and FabB proteins of Escherichia coli fatty acid synthesis by Enterococcus faecalis FabZ and FabF homologues. J. Biol. Chem. 279(33), 34489 (2004).
181. Kass LR. The antibacterial activity of 3-decynoyl-N-acetylcysteamine: inhibition in vivo of b-hydroxydecanoyl thioester dehydrase. J. Biol. Chem. 243(12), 3223-3228 (1968).
182. Morisaki M, Bloch K. Inhibition of b-hydroxydecanoyl thioester dehydrase by some allenic acids and their thioesters. Bioorg. Chem. 1, 188-193 (1971).
183. Sharma SK, Kapoor M, Ramya TNC et al. Identification, characterization, and inhibition of Plasmodium falciparum b-hydroxyacyl-acyl carrier protein dehydratase (FabZ). J. Biol. Chem. 278(46), 45661-45671 (2003). (Pubitemid 37432708)
184. Lu H, Tonge PJ. Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei. Biochemistry 49(6), 1281-1289 (2010).
185. Heath RJ, Rock CO. A triclosan-resistant bacterial enzyme. Nature 406, 145-146 (2000).
186. Rozwarski DA, Vilcheze C, Sugantino M, Bittman R, Sacchettini JC. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J. Biol. Chem. 274(22), 15582-15589 (1999).
187. Parikh S, Moynihan DP, Xiao G, Tonge PJ. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry 38(41), 13623-13634 (1999).
188. Rafi S, Novichenok P, Kolappan S et al. Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli. J. Biol. Chem. 281(51), 39285-39293 (2006). (Pubitemid 46041887)
189. Banerjee A, Dubnau E, Quemard A et al. ihA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227-230 (1994). (Pubitemid 24067929)
190. Heath RJ, Yu Y-T, Shapiro MA, Olson E, Rock CO. Broad-spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273, 30316-3032 (1998).
191. Baldock C, de Boer GJ, Rafferty JB, Stuitje AR, Rice DW. Mechanism of action of diazaborines. Biochem. Pharm. 55, 1541-1549 (1998). (Pubitemid 28223445)
192. Davis MC, Franzblau SG, Martin AR. Synthesis and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro. Bioorg. Med. Chem. Lett. 8, 843-846 (1998). (Pubitemid 28160051)
193. Payne DJ, Miller WH, Berry V et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46(10), 3118-3124 (2002).
194. Seefeld MA, Miller WH, Newlander KA et al. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem. 46, 1627 (2003).
195. Hevener KE, Mehboob S, Su PC et al. Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching. J. Med. Chem. 55(1), 268-279 (2012).
196. Vilcheze C, Jacobs WR Jr. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol. 61, 35-50 (2007). (Pubitemid 350058198)
197. Mdluli K, Slayden RA, Zhu Y et al. Inhibition of a Mycobacterium tuberculosis-ketoacyl ACP synthase by isoniazid. Science 280, 1607-1610 (1998). (Pubitemid 28277706)
198. Ghosh AK, Xi K. Total synthesis of (-)-platensimycin, a novel antibacterial agent. J. Org. Chem. 74(3), 1163-1170 (2009).
199. Argyrou A, Vetting MW, Aladegbami B, Blanchard JS. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat. Struct. Mol. Biol. 13, 408-413 (2006). (Pubitemid 43881580)
200. Rouse DA, Li Z, Bai G-H, Morris. SL. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39(11), 2472-2477 (1995).
201. DeBarber AE, Mdluli K, Bosman M, Bekker L-G, Barry CE 3rd. Ethionamide activation and sensitivity in multidrugresistant Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 97(17), 9677-9682 (2000). (Pubitemid 30650835)
202. Lu H, Tonge PJ. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc. Chem. Res. 41(1), 11-20 (2008).
203. Baldock C, Rafferty JB, Sedelnikova SE et al. A mechanism of drug action revealed by structural studies of enoyl reductase. Science 274, 2107-2110 (1996). (Pubitemid 27020709)
204. Roujeinikova A, Sedelnikova S, de Boer GJ et al. Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition. J. Biol. Chem. 274, 30811-30817 (1999).
205. de Boer GJ, Pielage GJ, Nijkamp HJ et al. Molecular genetic analysis of enoyl-acyl carrier protein reductase inhibition by diazoborine. Mol. Microbiol. 31, 443-450 (1999). (Pubitemid 29046087)
206. Aiello AE, Larson E. Antibacterial cleaning and hygiene products as an emerging risk factor for antibiotic resistance in the community. Lancet Infect. Dis. 3(8), 501-506 (2003). (Pubitemid 36919096)
207. Ward WHJ, Holdgate GA, Rowsell S et al. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 38, 12514-12525 (1999).
208. McMurry LM, Oethinger M, Levy SB. Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol. Lett. 166, 305-309 (1998). (Pubitemid 128384175)
209. Sullivan TJ, Truglio JJ, Boyne ME et al. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1(1), 43-53 (2006).
210. Sivaraman S, Sullivan TJ, Johnson F et al. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. J. Med. Chem. 47(3), 509-518 (2004). (Pubitemid 38129710)
211. Liu BQ, Wang YQ, Fillgrove KL, Anderson VE. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother. Pharmacol. 49(3), 187-193 (2002). (Pubitemid 34185591)
212. Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob. Agents Chemother. 53(8), 3544-3548 (2009).
213. Bogdanovich T, Clark C, Kosowska-Shick K, Dewasse B, McGhee P, Appelbaum PC. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Antimicrob. Agents Chemother. 51(11), 4191-4195 (2007). (Pubitemid 350057828)
214. Park HS, Yoon YM, Jung SJ, Kim CM, Kim JM, Kwak JH. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J. Antimicrob. Chemother. 60(3), 568-574 (2007). (Pubitemid 47299870)
215. Beigneux AP, Kosinski C, Gavino B, Horton JD, Skarnes WC, Young SG. ATP-citrate lyase deficiency in the mouse. J. Biol. Chem. 279(10), 9557-9564 (2004). (Pubitemid 38296024)
216. Sugden MC, Holness MJ. Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2(2), 151-165 (2002).
217. Bauer DE, Hatzivassiliou G, Zhao FP, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24(41), 6314-6322 (2005). (Pubitemid 43080054)
218. Watson JA, Fang M, Lowenste JM. Tricarballylate and hydroxycitrate- substrate and inhibitor of ATP-citrate oxaloacetate lyase. Arch. Biochem. Biophys. 135(1-2), 209-217 (1969).
219. Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent-a randomized controlled trial. J. Am. Med. Assoc. 280(18), 1596-1600 (1998). (Pubitemid 28520648)
220. Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Stohs SJ. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). Mol. Cell. Biochem. 238(1-2), 89-103 (2002). (Pubitemid 35023532)
221. Pearce NJ, Yates JW, Berkhout TA et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids-hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J. 334, 113-119 (1998).
222. Ma ZP, Chu CH, Cheng D. A novel direct homogeneous assay for ATP citrate lyase. J. Lipid Res. 50(10), 2131-2135 (2009).
223. Hatzivassiliou G, Zhao FP, Bauer DE et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8(4), 311-321 (2005). (Pubitemid 41443416)
224. Oleynek JJ, Barrow CJ, Burns MP et al. Anthrones, naturally-occurring competitive inhibitors of adenosine-triphosphate-citrate lyase. Drug Dev. Res. 36(1), 35-42 (1995).
225. Chu KY, Lin Y, Hendel A, Kulpa JE, Brownsey RW, Johnson JD. ATP-citrate lyase reduction mediates palmitate-induced apoptosis in pancreatic beta cells. J. Biol. Chem. 285(42), 32606-32615 (2010).
226. Pemble CWT, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat. Struct. Mol. Biol. 14(8), 704-709 (2007). (Pubitemid 47220052)
227. Hadvary P, Sidler W, Meister W, Vetter W, Wolfer H. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active-site serine of pancreatic lipase. J. Biol. Chem. 266(4), 2021-2027 (1991). (Pubitemid 21909023)
228. Hill JO, Hauptman J, Anderson JW et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am. J. Clin. Nutr. 69(6), 1108-1116 (1999). (Pubitemid 29252041)
229. Yang PY, Liu K, Ngai MH, Lear MJ, Wenk MR, Yao SQ. Activity-based proteome profiling of potential cellular targets of orlistat-an FDA-approved drug with anti-tumor activities. J. Am. Chem. Soc. 132(2), 656-666 (2010).
230. Martinez-Villaluenga C, Rupasinghe SG, Schuler MA, de Mejia EG. Peptides from purified soybean beta-conglycinin inhibit fatty acid synthase by interaction with the thioesterase catalytic domain. FEBS J. 277(6), 1481-1493 (2010).
231. Richardson RD, Smith JW. Novel antagonists of the thioesterase domain of human fatty acid synthase. Mol. Cancer Ther. 6(7), 2120-2126 (2007). (Pubitemid 47052503)
232. Zhang W, Chakravarty B, Zheng F et al. Crystal structure of FAS thioesterase domain with polyunsaturated fatty acyl adduct and inhibition by dihomo-gamma-linolenic acid. Proc. Natl Acad. Sci. USA 108(38), 15757-15762 (2011).
233. Grimes KD, Lu YJ, Zhang YM et al. Novel acyl phosphate mimics that target PlsY, an essential acyltransferase in gram-positive bacteria. ChemMedChem 3(12), 1936-1945 (2008).
234. Ramsay RR, Gandour RD, van der Leij FR. Molecular enzymology of carnitine transfer and transport. Biochim. Biophys. Acta 1546(1), 21-43 (2001). (Pubitemid 32217800)
235. Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol. Aspects Med. 25(5-6), 495-520 (2004). (Pubitemid 39195073)
236. Foster DW. The role of the carnitine system in human metabolism. Ann. NY Acad. Sci. 1033, 1-16 (2004). (Pubitemid 39656734)
237. Kuhajda FP, Ronnett GV. Modulation of carnitine palmitoyltransferase-1 for the treatment of obesity. Curr. Opin. Investig. Drugs 8(4), 312-317 (2007). (Pubitemid 46557992)
238. Ronnett GV, Kleman AM, Kim EK, Landree LE, Tu Y. Fatty acid metabolism, the central nervous system, and feeding. Obesity 14(SUPPL. 5), 201S-207S (2006).
239. Anderson RC, Balestra M, Bell PA et al. Antidiabetic agents: a new class of reversible carnitine palmitoyltransferase I inhibitors. J. Med. Chem. 38(18), 3448-3450 (1995).
240. Jenkins DL, Griffith OW. Antiketogenic and hypoglycemic effects of aminocarnitine and acylaminocarnitines. Proc. Natl Acad. Sci. USA 83(2), 290-294 (1986). (Pubitemid 16079998)
241. Giannessi F, Pessotto P, Tassoni E et al. Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity. J. Med. Chem. 46(2), 303-309 (2003). (Pubitemid 36078147)
242. Rufer AC, Thoma R, Benz J et al. The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment. Structure 14(4), 713-723 (2006).
243. Anderson RC. Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM? Curr. Pharm. Des. 4(1), 1-16 (1998). (Pubitemid 28090065)
244. Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun. 285(2), 217-223 (2001). (Pubitemid 32918056)
245. Altenbern RA. Cerulenin-inhibited cells of Staphylococcus aureus resume growth when SUPPL.emented with either a saturated or an unsaturated fatty acid. Antimicrob. Agents Chemother. 11, 574-576 (1977). (Pubitemid 8065624)
246. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458(7234), 83-86 (2009).
247. Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc. Natl Acad. Sci. USA 108(37), 15378-15383 (2011).
248. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS ONE 5(3), e9836 (2010).
249. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature 474(7351), 327-336 (2011).
250. Parker RA, Flint OP, Mulvey R et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol. Pharmacol. 67(6), 1909-1919 (2005). (Pubitemid 41007773)
251. Alexander JW. Immunonutrition: the role of omega-3 fatty acids. Nutrition 14(7-8), 627-633 (1998). (Pubitemid 28345462)
252. Pommerville JC. Fundamentals of Microbiology. Jones & Bartlett Learning, Sudbury, MA, USA, 115(2008).
253. Daffé M, Reyrat J-M. The Mycobacterial Cell Envelope. ASM Press, Washington, DC, USA, 4, (2008)
254. He X, Reeve AM, Desai UR, Kellogg GE, Reynolds KA. 1,2-dithiole-3-ones as potent inhibitors of the bacterial 3-ketoacyl acyl carrier protein synthase III (FabH). Antimicrob. Agents Chemother. 48(8), 3093 (2004).
255. Khandekar SS, Gentry DR, Aller GSV et al. Identification, substrate specificity, and inhibition of the Streptococcus pneumoniae b-ketoacyl-acyl carrier protein synthase III (FabH). J. Biol. Chem. 276(32), 30024 (2001).
256. Noto T, Miyakawa S, Oishi H, Endo H, Okazaki. H. Thiolactomycin, a new antibiotic. III. In vitro antibacterial activity J. Antibiot. (Tokyo) 35, 401 (1982).
257. Rosner JL. Susceptibilities of oxyR regulon mutants of Escherichia coli and Salmonella typhimurium to isoniazid. Antimicrob. Agents Chemother. 37, 2251-2253 (1993). (Pubitemid 23298223)
258. Rawat R, Whitty A, Tonge PJ. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl Acad. Sci. USA 100(24), 13881-13886 (2003). (Pubitemid 37499160)
259. Baulard AR, Betts JC, Engohang-Ndong J et al. Activation of the pro-drug ethionamide is regulated in Mycobacteria. Proc. Natl Acad. Sci. USA 275(36), 28326-28331 (2000).
260. Wang F, Langley R, Gulten G et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J. Exp. Med. 204(1), 73-78 (2007). (Pubitemid 46148758)
261. Jang KP, Kim CH, Na SW et al. 7-phenylplatensimycin and 11-methyl-7-phenylplatensimycin: more potent analogs of platensimycin. Bioorg. Med. Chem. Lett. 20(7), 2156-2158 (2009).
262. Patra M, Gasser G, Pinto A et al. Synthesis and biological evaluation of chromium bioorganometallics based on the antibiotic platensimycin lead structure. ChemMedChem 4(11), 1930-1938 (2009).
263. Tiefenbacher K, Gollner A, Mulzer J. Syntheses and antibacterial properties of iso-platencin, Cl-iso-platencin and Cl-platencin: identification of a new lead structure. Chem. Eur. J. 16(31), 9616-9622 (2010).
264. Jang KP, Kim CH, Na SW, Kim H, Kang H, Lee E. Isoplatensimycin: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 19(16), 4601-4602 (2009).
265. Nicolaou KC, Tang Y, Wang J, Stepan AF, Li A, Montero A. Total synthesis and antibacterial properties of carbaplatensimycin. J. Am. Chem. Soc. 129(48), 14850-14851 (2007). (Pubitemid 350230697)
266. Nicolaou KC, Lister T, Denton RM, Montero A, Edmonds DJ. Adamantaplatensimycin: a bioactive analogue of platensimycin. Angew. Chem. Int. Ed. Engl. 46(25), 4712-4714 (2007). (Pubitemid 46997468)
267. Zhang C, Ondeyka J, Herath K et al. Platensimycin and platencin congeners from Streptomyces platensis. J. Nat. Prod. 74(3), 329-340 (2011).
268. Singh SB, Jayasuriya H, Ondeyka JG et al. Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J. Am. Chem. Soc. 128(36), 11916-11920 (2006). (Pubitemid 44360228)
269. Zhang CW, Ondeyka J, Zink DL, Burgess B, Wang J, Singh SB. Isolation, structure and fatty acid synthesis inhibitory activities of platensimycin B-1-B-3 from Streptomyces platensis. Chem. Comm. (40), 5034-5036 (2008).
270. Wang J, Sintim HO. Dialkylamino-2,4-dihydroxybenzoic acids as easily synthesized analogues of platensimycin and platencin with comparable antibacterial properties. Chem. Eur. J. 17(12), 3352-3357 (2011).
271. Barykina OV, Rossi KL, Rybak MJ, Snider BB. Synthesis and antibacterial properties of (-)-nor-platencin. Org. Lett. 11(22), 5334-5337 (2009).
272. Singh SB, Jayasuriya H, Herath KB et al. Isolation, enzyme-bound structure, and activity of platensimycin A1 from Streptomyces platensis. Tetra. Lett. 50(37), 5182-5185 (2009).
273. Zhang CW, Ondeyka J, Guan ZQ et al. Isolation, structure and biological activities of platensimycin B-4 from Streptomyces platensis. J. Antibiotics 62(12), 699-702 (2009).